Tue, Aug 11 01:25 PM

Eikon selects 0.60 mg/m2 dose for melanoma trial TeLuRide-006

Investing.com•Tue, Aug 11, 2026, 11:36 AM•2 min read

Developing story — details emerging. Check the source link for the latest updates.

Source: [Investing.com](https://www.investing.com/news/company-news/eikon-selects-060-mgm2-dose-for-melanoma-trial-teluride006-93CH-4851364)

📰 Read Full Story

This is an aggregated headline summary. For the complete report, visit the original publisher.

Continue Reading at Investing.com ↗

#finance #eikon #selects #dose #melanoma #trial #teluride

More Headlines

FinanceSeeking Alpha• 7m ago

Microsoft Vs. AMD: Investors May Be Watching The Wrong Variables (Panel Regression)

Developing story — details emerging. Check the source link for the latest updates.

FinanceSeeking Alpha• 8m ago

Teledyne: Varex Acquisition Strengthens The Buy Case

Developing story — details emerging. Check the source link for the latest updates.

FinanceSeeking Alpha• 8m ago

Wharf Real Estate Investment Company Limited (WHREY) Q2 2026 Earnings Call Transcript

Developing story — details emerging. Check the source link for the latest updates.

FinanceSeeking Alpha• 8m ago

Remedy Entertainment Oyj (RMDEF) Q2 2026 Earnings Call Transcript

Developing story — details emerging. Check the source link for the latest updates.

FinanceSeeking Alpha• 8m ago

Upwork Inc. (UPWK) Q2 2026 Earnings Call Transcript

Developing story — details emerging. Check the source link for the latest updates.

FinanceCNBC• 9m ago

Pakistan signals progress on U.S.-Iran deal as Washington and Tehran trade reparation demands

The dueling positions Washington and Tehran staked out showed how far apart the two sides remain even as both talked of winding down regional hostilities.